Supplementary Table S2. *ELISPOT responses to AAV or CNGB3 peptides after subretinal injection of AAV5-PR2.1-hCNGB3 or AAV5-PR2.1-cCNGB3 in CNGB3-mutant dogs*

			SFU/million PBMC													
				AAV5			*Human CNGB3*				*Canine CNGB3*				*SFU/20,000 PBMC*
Animal ID	*Study week*	*Vector dose (vg/eye)*	Medium	*A*	*B*	*C*	*A*	*B*	*C*	*D*	*A*	*B*	*C*	*D*	*PMA/ionomycin*
M730	6	5×10^{11}	5	20	50	25	25	35	25	45	**80**	30	0	NT	54
M728	12	5×10^{11}	15	35	40	35	40	**55**	20	40	15	30	45	30	149
M729	12	5×10^{11}	15	15	25	35	30	**55**	35	30	**65**	**60**	30	30	219
M730	12	5×10^{11}	8	40	50	**68**	40	**68**	38	28	25	48	53	25	149
M731	12	5×10^{10}	8	10	25	23	23	18	18	3	3	5	35	5	94
M732	12	5×10^{10}	25	50	18	0	18	20	13	5	8	8	15	8	229
M733	12	5×10^{10}	48	38	25	13	25	23	20	13	15	15	23	15	158

Results are expressed as the number of spot-forming cells (SFU) per the indicted number of peripheral blood mononuclear cells (PBMC). Positive responses (≥55 SFU/million PBMC and more than three times the medium control value) are shown in **bold**.

PMA, phorbol myristic acid; AAV5, adeno-associated virus serotype 5; CNGB3, cyclic nucleotide gated channel beta subunit; NT, not tested. A, B, C, and D designate pools of peptides used for stimulation of T cells in the ELISPOT assay.